EpiCept Corporation

As of August 25, 2013, EpiCept Corporation was acquired by Immune Pharmaceuticals Ltd., in a reverse merger transaction. EpiCept Corporation, a specialty pharmaceutical company, focuses on the clinical development and commercialization of pharmaceutical products for the treatment of pain and cancer. The company develops AmiKet, a prescription topical analgesic cream that has completed Phase II clinical trials for the treatment of peripheral neuropathies. It also develops Azixa, an apoptosis inducer that is in Phase II clinical development for the treatment of brain cancer. In addition, the company is developing crolibulin, a novel small molecule vascular disruption agent and apoptosis inducer, which is in a Phase Ib/II clinical trial for the treatment of patients with solid tumors. The company has strategic alliance with DURECT Corporation. EpiCept Corporation was founded in 1993 and is based in Tarrytown, New York.